The earnings call highlighted robust sales growth, upgraded guidance, and strong performance of key brands, alongside promising pipeline developments. However, there are challenges such as moderated growth for Cosentyx, a slowdown in China, and potential generic competition for Entresto.

Company Guidance -

Q3 2025

During the Novartis Q2 2025 earnings call, the company reported substantial financial progress, including an 11% increase in sales and a 21% rise in core operating income, both in constant currency. The core margin improved by 340 basis points to reach 42.2%, while core EPS grew by 24% to $2.42. Free cash flow also surged, achieving a 37% increase to $6.3 billion. Novartis raised its full-year 2025 bottom line guidance, now anticipating core operating income growth in the low teens. The company highlighted significant milestones, such as the submission of OAV101 IT in the U.S. and Europe and key advancements in its portfolio, including a 64% growth in Kisqali and a 33% rise in Kesimpta. Additionally, Novartis announced a new $10 billion share buyback program, emphasizing its balanced approach to capital allocation while maintaining a focus on bolt-on acquisitions and internal R&D investments.

Double-Digit Sales Growth

Novartis delivered an 11% increase in sales and a 21% increase in core operating income in constant currency.

Upgraded Full Year Guidance

Novartis upgraded its full-year 2025 bottom line guidance with sales expected to grow in the high single digits and core operating income in the low teens.

Strong Performance of Key Brands

Priority brands showed robust growth, with Kisqali up 64%, Kesimpta up 33%, and Pluvicto experiencing a 30% increase in the quarter.

New $10 Billion Share Buyback Program

A new share buyback program of up to $10 billion is initiated, targeted for completion by the end of 2027.

Promising Pipeline Developments

Significant pipeline advancements include positive Phase III results for Pluvicto in metastatic hormone-sensitive prostate cancer and promising Phase II results for Remibrutinib in food allergy.

Novartis AG (DE:NOT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:NOT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 28, 2025	2025 (Q3)	1.89 / -	1.762	―	―	―
Jul 17, 2025	2025 (Q2)	2.01 / 2.07	1.685	22.84% (+0.38)	―	―
Apr 29, 2025	2025 (Q1)	1.81 / 1.95	1.54	26.67% (+0.41)	―	―
Jan 31, 2025	2024 (Q4)	1.54 / 1.69	1.309	29.41% (+0.38)	―	―
Oct 29, 2024	2024 (Q3)	1.66 / 1.76	1.489	18.39% (+0.27)	―	―
Jul 18, 2024	2024 (Q2)	1.58 / 1.69	1.484	13.61% (+0.20)	―	―
Apr 23, 2024	2024 (Q1)	1.44 / 1.54	1.387	11.04% (+0.15)	―	―
Jan 31, 2024	2023 (Q4)	1.41 / 1.31	1.233	6.18% (+0.08)	―	―
Oct 24, 2023	2023 (Q3)	1.43 / 1.49	1.282	16.15% (+0.21)	―	―
Jul 18, 2023	2023 (Q2)	1.40 / 1.48	1.265	17.24% (+0.22)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:NOT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 17, 2025	€102.02	€100.30	-1.69%
Apr 29, 2025	€80.34	€80.34	0.00%
Jan 31, 2025	€76.70	€76.70	0.00%
Oct 29, 2024	€76.70	€76.70	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Novartis AG (DE:NOT) report earnings?

Novartis AG (DE:NOT) is schdueled to report earning on Oct 28, 2025, TBA (Confirmed).

What is Novartis AG (DE:NOT) earnings time?

Novartis AG (DE:NOT) earnings time is at Oct 28, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Novartis AG stock?

The P/E ratio of Novartis AG is N/A.

What is DE:NOT EPS forecast?

DE:NOT EPS forecast for the fiscal quarter 2025 (Q3) is 1.89.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing